Julia Sidenius Johansen

Medicin og biovidenskab

1. Biomarkers 100%
2. Colorectal Neoplasms 71%
3. Pancreatic Neoplasms 58%
4. Interleukin-6 56%
5. Serum 55%
6. Survival 54%
7. Adenocarcinoma 50%
8. Rheumatoid Arthritis 37%
9. C-Reactive Protein 37%
10. Neoplasms 32%
11. Cell-Free Nucleic Acids 30%
12. MicroRNAs 26%
13. Biliary Tract Neoplasms 25%
14. Adalimumab 23%
15. Mortality 21%
16. Tumor Necrosis Factor Inhibitors 20%
17. Inflammation 20%
18. Methotrexate 18%
19. Coronary Artery Disease 18%
20. Therapeutics 18%
21. Carcinoembryonic Antigen 17%
22. Drug Therapy 17%
23. Bevacizumab 17%
24. Confidence Intervals 16%
25. Cetuximab 15%
26. Oxaliplatin 15%
27. Tumor Biomarkers 14%
28. Population 14%
29. Vascular Endothelial Growth Factor A 13%
30. Mutation 13%
31. Carbohydrates 12%
32. Randomized Controlled Trials 12%
33. Melanoma 12%
34. Proteins 11%
35. Glioblastoma 11%
36. Fibrosis 11%
37. Circulating Tumor DNA 10%
38. Capecitabine 10%
39. Blood Proteins 10%
40. Placebos 10%
41. Chitinase-3-Like Protein 1 10%
42. Healthy Volunteers 10%
43. Progression-Free Survival 10%
44. Tumor Necrosis Factor-alpha 10%
45. Antigens 9%
46. Neutrophils 9%
47. Adjuvant Chemotherapy 9%
48. Genotype 9%
49. Collagen 9%
50. Antirheumatic Agents 9%